Allergy Therapeutics plc (LON:AGY – Get Free Report) hit a new 52-week low during trading on Monday. The company traded as low as GBX 4 and last traded at GBX 4.47, with a volume of 150,247 shares traded. The stock had previously closed at GBX 4.50.
Allergy Therapeutics Price Performance
The company has a market cap of £283.38 million, a price-to-earnings ratio of -4.61, a PEG ratio of -30.70 and a beta of 0.83. The company has a debt-to-equity ratio of 629.58, a quick ratio of 1.48 and a current ratio of 1.13. The business has a fifty day moving average price of GBX 5.10 and a 200 day moving average price of GBX 7.24.
About Allergy Therapeutics
Allergy Therapeutics is an international commercial biotechnology company focussed on the treatment and diagnosis of allergic disorders, including aluminium free immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries. Its broad pipeline of products in clinical development include vaccines for grass, tree and house dust mite, and peanut allergy vaccine in pre-clinical development.
Further Reading
- Five stocks we like better than Allergy Therapeutics
- Mr. Wonderful’s Test for AI Data Center Stocks: Power, Permits, and Tenants
- Alcoa Beat Earnings, But Can It Escape the Aluminum Bears?
- Insider Buying Is Rising at These 3 Regional Banks, But the Details Matter
- Illinois Tool Works Faces Headwinds—2 Alternatives Stand Out
Receive News & Ratings for Allergy Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergy Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
